Update: UCB’s Bepranemab Shows Promise In Alzheimer’s
UCB's Phase 2a study of bepranemab, an anti-tau antibody for Alzheimer's, will be presented at CTAD 2024. The study shows promise in delaying disease progression.
CHMP Recommends Wainzua For EU Approval For Hereditary Amyloidosis
AstraZeneca's Wainzua (eplontersen) has been recommended for approval in the EU by CHMP for treating adult patients with hereditary transthyretin-mediated amyloidosis polyneuropathy.
Update: Merck’s Clesrovimab Reduced RSV Disease, Hospitalization In Infants
Merck & Co., Inc. released news about their Clesrovimab (MK-1654) monoclonal antibody reducing RSV disease and hospitalizations in infants.
AstraZeneca Set to Showcase New Cancer Research at ASCO 2024
Plenary Presentations Highlight Tagrisso and Imfinzi’s Potential in Early Lung Cancer London, UK – This Tuesday, AstraZeneca confirmed that it is set to present new data across its oncology portfolio…
Truqap Plus Faslodex Recommended for EU Approval in Advanced Breast Cancer Treatment
AstraZeneca’s Combination Therapy Shows Significant Efficacy in Phase III Trial Cambridge, UK- On Monday, AstraZeneca’s combination of Truqap (capivasertib) with Faslodex (fulvestrant) received a recommendation for approval from the Committee…
Hikma Pharmaceuticals Reports Strong Start to 2024 Across All Business Segments, Confirms Full Year Guidance
Consistent Growth and Expanded Market Reach Highlight Early Success; Final Dividend Announced London, UK— This Thursday, Hikma Pharmaceuticals PLC provided a trading update in advance of its Annual General Meeting,…
Update: Merck Invests €300 Million in New Bio-Pharmaceutical Research Center
German Chancellor Olaf Scholz and Merck Celebrate Laying for Advanced Research Facility Darmstadt, Germany — This Thursday, Merck announced an investment of over €300 million in the construction of a…